N-acetylcysteine possesses antidepressant-like activity through reduction of oxidative stress: Behavioral and biochemical analyses in rats

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 39, Issue 2, 2012, Pages 280-287

  Smaga, Irena ^a   Pomierny, Bartosz ^a   Krzyzanowska, Weronika ^a   Pomierny Chamioło, Lucyna ^a   Miszkiel, Joanna ^b   Niedzielska, Ewa ^a   Ogórka, Agata ^a   Filip, Małgorzata ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressant; Depression; Olfactory bulbectomy; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; IMIPRAMINE; SOLVENT; SUPEROXIDE DISMUTASE;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN HOMOGENATE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; EX VIVO STUDY; FORCED SWIMMING TEST; FRONTAL CORTEX; HIPPOCAMPUS; IMMOBILIZATION; IN VIVO STUDY; LOCOMOTION; MALE; MORNING DOSAGE; NONHUMAN; OLFACTORY BULBECTOMY; OXIDATIVE STRESS; RAT; SHAM PROCEDURE; TREATMENT DURATION;

ACETYLCYSTEINE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; IMIPRAMINE; IMMOBILITY RESPONSE, TONIC; MALE; MOTOR ACTIVITY; OLFACTORY BULB; OXIDATION-REDUCTION; OXIDATIVE STRESS; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 84867014081     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.06.018     Document Type: Article

References (53)

1. Aruoma O.I., Halliwell B., Hoey B.M., Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989, 6:593-597.
2. Baker D.A., Xi Z.X., Shen H., Swanson C.J., Kalivas P.W. The origin and neuronal function of in vivo nonsynaptic glutamate. J Neurosci 2002, 22:9134-9141.
3. Behr G.A., Moreira J.C., Frey B.N. Preclinical and clinical evidence of antioxidant effects of antidepressant agents: implications for the pathophysiology of major depressive disorder. Oxid Med Cell Longev 2012, 2012:609421.
4. Ben-Shachar D., Zuk R., Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995, 64:718-723.
5. Benzie I.F., Strain J.J. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power" the FRAP assay. Anal Biochem 1996, 239:70-76.
6. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetylcysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008, 64:468-475.
7. Berk M., Dean O., Cotton S.M., Gama C.S., Kapczinski F., Fernandes B.S., et al. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 2011, 135:389-394.
8. Bilici M., Efe H., Köroǧlu M.A., Uydu H.A., Bekaroǧlu M., Deǧer O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001, 64:43-51.
9. Campo B., Kalinichev M., Lambeng N., El Yacoubi M., Royer-Urios I., Schneider M., et al. Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J Neurogenet 2011, 25:152-166.
10. Cao X., Liu Z., Xu C., Li J., Gao Q., Sun N., et al. Disrupted resting-state functional connectivity of the hippocampus in medication-naïve patients with major depressive disorder. J Affect Disord 2012, [Mar 27 Epub ahead of print].
11. Detke M.J., Rickels M., Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 1995, 121:66-72.
12. Duman R.S., Nakagawa S., Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001, 25:836-844.
13. Farr S.A., Poon H.F., Dogrukol-Ak D., Drake J., Banks W.A., Eyerman E., et al. The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem 2003, 84:1173-1183.
14. Fell M.J., Witkin J.M., Falcone J.F., Katner J.S., Perry K.W., Hart J., et al. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J Pharmacol Exp Ther 2011, 336:165-177.
15. Ferreira F., Biojone C., Joca S., Guimaraes F. Antidepressant-like effects of N-acetyl-l-cysteine in rats. Behav Pharmacol 2008, 19:747-750.
16. Feyissa A.M., Woolverton W.L., Miguel-Hidalgo J.J., Wang Z., Kyle P.B., Hasler G., et al. Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:279-283.
17. Frankowska M., Gołda A., Wydra K., Gruca P., Papp M., Filip M. Effects of imipramine or GABA(B) receptor ligands on the immobility, swimming and climbing in the forced swim test in rats following discontinuation of cocaine self-administration. Eur J Pharmacol 2010, 627:142-149.
18. Gandhi S., Abramov A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012, 2012:428010.
19. Gere-Paszti E., Jakus J. The effect of N-acetylcysteine on amphetamine-mediated dopamine release in rat brain striatal slices by ion-pair reversed-phase high performance liquid chromatography. Biomed Chromatogr 2009, 23:658-664.
20. Greenlund L.J., Deckwerth T.L., Johnson E.M. Superoxide dismutase delays neuronal apoptosis: a role for reactive oxygen species in programmed neuronal death. Neuron 1995, 14:303-315.
21. Hashimoto K., Tsukada H., Nishiyama S., Fukumoto D., Kakiuchi T., Shimizu E., et al. Effects of N-acetyl-l-cysteine on the reduction of brain dopamine transporters in monkey treated with methamphetamine. Ann N Y Acad Sci 2004, 1025:231-235.
22. Hermida-Ameijeiras A., Méndez-Alvarez E., Sánchez-Iglesias S., Sanmartín-Suárez C., Soto-Otero R. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem Int 2004, 45:103-116.
23. Kim E., Shirvalkar P., Herrera D.G. Regulation of neurogenesis in the aging vertebrate brain: role of oxidative stress and neuropsychiatric factors. Clin Neurosci Res 2003, 2:285-293.
24. Koob G.F. Animal models of psychiatric disorders. Handb Clin Neurol 2012, 106:137-166.
25. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., et al. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2008, 33:2187-2199.
26. Leonard B.E., Tuite M. Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol 1981, 22:251-286.
27. Li X.M., Chlan-Fourney J., Juorio A.V., Bennett V.L., Shrikhande S., Bowen R.C. Antidepressants upregulate messenger RNA levels of the neuroprotective enzyme superoxide dismutase (SOD1). J Psychiatry Neurosci 2000, 25:43-47.
28. Lieb K., Andrae J., Reisert I., Pilgrim C. Neurotoxicity of dopamine and protective effects of the NMDA receptor antagonist AP-5 differ between male and female dopaminergic neurons. Exp Neurol 1995, 134:222-229.
29. Lowry O.H., Rosenbrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
30. Lucca G., Comim C.M., Valvassori S.S., Réus G.Z., Vuolo F., Petronilho F., et al. Effects of chronic mild stress on the oxidative parameters in the rat brain. Neurochem Int 2009, 54:358-362.
31. Maciel E.N., Vercesi A.E., Castilho R.F. Oxidative stress in Ca(2+)-induced membrane permeability transition in brain mitochondria. J Neurochem 2001, 79:1237-1245.
32. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:676-692.
33. Magalhaes P.V., Dean O.M., Bush A.I., Copolov D.L., Malhi G.S., Kohlmann K., et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 2011, 33:374-378.
34. Matrisciano F., Zusso M., Panaccione I., Turriziani B., Caruso A., Iacovelli L., et al. Synergism between fluoxetine and the mGlu2/3 receptor agonist, LY379268, in an in vitro model for antidepressant drug-induced neurogenesis. Neuropharmacology 2008, 54:428-437.
35. Michel T.M., Frangou S., Thiemeyer D., Camara S., Jecel J., Nara K., et al. Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder - a postmortem study. Psychiatry Res 2007, 151:145-150.
36. Misra H.P., Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972, 247:3170-3175.
37. Moncada S., Bolanos J.P. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006, 97:1676-1689.
38. Moran M.M., McFarland K., Melendez R.I., Kalivas P.W., Seamans J.K. Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci 2005, 25:6389-6393.
39. Murray C.J., Lopez A.D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349:1436-1442.
40. Nestler E.J. Molecular mechanisms of drug addiction. Neuropharmacology 2004, 47:24-32.
41. Neuwelt E.A., Pagel M.A., Hasler B.P., Deloughery T.G., Muldoon L.L. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 2001, 61:7868-7874.
42. Novío S., Núñez M.J., Amigo G., Freire-Garabal M. Effects of fluoxetine on the oxidative status of peripheral blood leucocytes of restraint-stressed mice. Basic Clin Pharmacol Toxicol 2011, 109:365-371.
43. Pal S.N., Dandiya P.C. Glutathione as a cerebral substrate in depressive behavior. Pharmacol Biochem Behav 1994, 48:845-851.
44. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego. 4th ed.
45. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977, 229:327-336.
46. Rego A.C., Oliveira C.R. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem Res 2003, 28:1563-1574.
47. Réus G.Z., Stringari R.B., de Souza B., et al. Harmine and imipramine promote antioxidant activities in prefrontal cortex and hippocampus. Oxid Med Cell Longev 2010, 3:325-331.
48. Robinson O.J., Cools R., Carlisi C.O., Sahakian B.J., Drevets W.C. Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder. Am J Psychiatry 2012, 169:152-159.
49. Sarandol A., Sarandol E., Eker S.S., Erdinc S., Vatansever E., Kirli S. Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 2007, 22:67-73.
50. Stokes A.H., Hastings T.G., Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999, 55:659-665.
51. Tsuboi H., Tatsumi A., Yamamoto K., Kobayashi F., Shimoi K., Kinae N. Possible connections among job stress, depressive symptoms, lipid modulation and antioxidants. J Affect Disord 2006, 91:63-70.
52. Zafir A., Banu N. Antioxidant potential of fluoxetine in comparison to Curcuma longa in restraint-stressed rats. Eur J Pharmacol 2007, 572:23-31.
53. Zafir A., Ara A., Banu N. In vivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:220-228.